pH stability raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-06-05 and is reviewed periodically as new material appears.
Reconstitution is the process of dissolving a lyophilized peptide powder in a suitable liquid to produce a solution for laboratory or clinical use. The dry powder is typically a porous cake or fluffy solid formed by freeze-drying an aqueous or mixed-solvent preparation. Adding solvent restores the peptide to a dissolved state, but the result is not necessarily identical to the original pre-lyophilization solution. Factors such as pH, ionic strength, temperature, and the peptide's sequence influence how completely and quickly dissolution occurs. The term is distinct from dilution, which lowers concentration without changing the physical state of an already dissolved material.
Solvent selection depends on the peptide's charge, hydrophobicity, and intended application. Many lyophilized peptides dissolve readily in water, while others require a small amount of a miscible organic solvent, a dilute acid, or a dilute base before aqueous dilution. A buffer may be used when a stable pH range is known, but adding buffer salts can also promote aggregation or precipitation. Dissolution should be observed rather than assumed, because a clear solution does not prove that the peptide is monomeric or fully active. The order of solvent addition and the final volume matter for achieving the intended concentration.
Practical handling often includes dividing a reconstituted solution into single-use aliquots to limit freeze-thaw cycling. Vials made of low-binding plastic or glass with inert closures are common, and some protocols add a carrier protein or bulking agent to reduce adsorption. Filtration through a sterile filter may be used when a sterile solution is required, but filters can retain peptide if binding occurs. Mixing is usually gentle; vigorous vortexing can introduce air-liquid interfaces that promote aggregation. Each of these steps involves trade-offs between sterility, recovery, and analytical accuracy.
Storage recommendations for reconstituted peptides vary by sequence and intended use, so general rules remain broad. A common laboratory practice is to keep solutions cold, sometimes frozen, and protected from light, but freezing itself can damage certain peptides. The pH of the solution may be adjusted to a range where the peptide is most stable, though changing pH can also alter solubility. Documentation of reconstitution date, solvent, concentration, and storage conditions supports reproducibility. Stability data for a specific peptide are generally established by direct measurement rather than assumed from related compounds.
| Property | Value | Notes |
|---|---|---|
| Physical state before reconstitution | Lyophilized powder or cake | Appearance varies from fluffy to compact; not a solution. |
| Common solvent | Sterile or ultrapure water | Many peptides dissolve, but solubility is sequence-dependent. |
| Alternative solvent | Dilute acetic acid or acetonitrile/water | Used for hydrophobic or basic peptides; compatibility varies. |
| Typical storage after reconstitution | 2–8 °C short term; −20 °C or below for aliquots | Stability is peptide-specific; avoid repeated freeze-thaw. |
| Common analytical method | Reverse-phase HPLC | Assesses purity and concentration; mass spectrometry confirms identity. |
Once a peptide is in liquid form, its stability depends on temperature, pH, concentration, and the presence of oxygen or microbes. Refrigeration slows many degradation pathways, while freezing can extend storage for longer periods. Repeated freeze-thaw cycles are generally avoided because ice crystal formation and concentration changes can promote aggregation. Light exposure can also damage peptides that contain aromatic or sulfur-containing residues. A common laboratory practice is to divide a reconstituted stock into single-use aliquots before freezing, but the optimal storage condition remains peptide-specific and is often determined empirically.
Analytical checks help determine whether a reconstituted peptide matches its expected identity and purity; reverse-phase high-performance liquid chromatography separates components by hydrophobicity and can reveal degradation products or impurities. Mass spectrometry provides a mass measurement that supports sequence identity when compared with the theoretical value. Ultraviolet absorbance at 280 nm can estimate concentration for peptides containing tryptophan or tyrosine, though sequence-dependent extinction coefficients are needed. For shorter or non-aromatic peptides, other methods such as amino acid analysis may be required. These techniques describe the material rather than guarantee its biological effect.
Cloudiness, particles, or gel formation after reconstitution can signal incomplete dissolution, aggregation, or contamination. A clear solution is not proof of purity, and a cloudy one is not always unusable if the peptide is designed to form suspensions. pH measurement can identify whether the solution matches the intended range, and buffer exchange may be needed when the original solvent is incompatible. Sterile filtration is sometimes used for microbial control, but filters can adsorb peptides and reduce concentration. Documentation of lot number, solvent, volume, date, and storage condition supports later traceability in laboratory records.
Peptide reconstitution is the process of dissolving a lyophilized peptide in a liquid to form a solution for later use. Lyophilization removes water under vacuum, leaving a dry powder or porous cake. Reconstitution reintroduces solvent so the peptide molecules return to a dissolved state. The solvent may be purified water, a buffer, or a mixture containing an organic co-solvent. The choice depends on the peptide sequence, its charge, and its hydrophobicity.
During reconstitution, solvent penetrates the dry cake and breaks intermolecular contacts that held the peptide in solid form. Dissolution occurs as individual peptide molecules become surrounded by solvent. Hydrophobic regions can associate with one another instead of dissolving, which may produce turbidity or aggregates. pH and ionic strength influence the charge state of ionizable groups and therefore solubility. Buffer salts can help maintain a stable pH, but they can also participate in interactions that affect the final solution.
The concentration of a reconstituted peptide is calculated from the mass of peptide powder and the volume of solvent added. This calculation assumes the powder contains only peptide, but many preparations include counterions, water, or salts. Analytical methods such as ultraviolet absorbance or amino acid analysis can estimate actual peptide content. The relationship between nominal and actual concentration is an area where measurements matter. Open questions remain about how aggregation changes the effective concentration in solution.
The heavily phosphorylated β-sheet of caddisfly larvae contains strong negative charges which have been found to interact with di- and trivalent cations found naturally within the larvae's aquatic environment. These cations, including calcium, magnesium, and iron, are vital to maintaining the rigid structure of the silk's β-sheet. The ionic interactions between negatively charged serines and these cations produce a crystal with a unit cell of 5.9 Angstroms x 23.3 Angstroms x 17.3 Angstroms, as determined by X-Ray diffraction. The necessity of these cations was shown using EDTA to chelate and remove them from the protein structure, producing a mobile, noncrystalline protein. Reintroduction of monovalent ions failed to restore the crystalline structure, however reintroduction of calcium or other multivalent ions successfully restored the rigidity to the H-fibroin protein.
Adrenomedullin (ADM) is a peptide hormone that plays an important role in various physiological processes throughout the human body. Initially discovered in 1993 from a pheochromocytoma, a tumor of the adrenal medulla, this 52-amino acid peptide is now recognized for its diverse effects, including vasodilation, regulation of blood pressure, and maintenance of the vascular system. ADM is widely expressed in tissues and also found in the circulation, exerting its influence on the cardiovascular, lymphatic, and endocrine systems, as well as demonstrating anti-inflammatory and tissue-protective properties. In humans, ADM is encoded by the ADM gene. A similar peptide named adreomedullin2 was reported in rats in 2004, which exhibits a similar function.
CPC Scientific’s manufacturing processes primarily use solid-phase peptide synthesis (SPPS), first described by Robert Bruce Merrifield in 1963. SPPS allows peptides to be assembled stepwise on a solid support, enabling the preparation of long and complex sequences for use as active pharmaceutical ingredients (APIs), investigational drugs, and research materials. Researchers associated with the company have published studies involving peptide synthesis methodologies, including work related to hydrocarbon stapling. Products manufactured by the company have been used and cited in various scientific studies. Official website
The area under the effect curve (AUEC) is an integral of the effect of a drug over time, estimated as a previously-established function of concentration. It was proposed to be used instead of AUC in animal-to-human dose translation, as computer simulation shows that it could cope better with half-life and dosing schedule variations than AUC. This is an example of a PK/PD model, which combines pharmacokinetics and pharmacodynamics. Cmax (pharmacology) Cmean (pharmacology) "Area Under Curve" of the Receiver operating characteristic
Sources: en.wikipedia.org
The first class of adenylyl cyclases occur in many bacteria including E. coli (as CyaA P00936 [unrelated to the Class II enzyme]). This was the first class of AC to be characterized. It was observed that E. coli deprived of glucose produce cAMP that serves as an internal signal to activate expression of genes for importing and metabolizing other sugars. cAMP exerts this effect by binding the transcription factor CRP, also known as CAP. Class I AC's are large cytosolic enzymes (~100 kDa) with a large regulatory domain (~50 kDa) that indirectly senses glucose levels. As of 2012, no crystal structure is available for class I AC. Some indirect structural information is available for this class. It is known that the N-terminal half is the catalytic portion, and that it requires two Mg2+ ions. S103, S113, D114, D116 and W118 are the five absolutely essential residues. The class I catalytic domain (Pfam PF12633) belongs to the same superfamily (Pfam CL0260) as the palm domain of DNA polymerase beta (Pfam PF18765). Aligning its sequence onto the structure onto a related archaeal CCA tRNA nucleotidyltransferase (PDB: 1R89) allows for assignment of the residues to specific functions: γ-phosphate binding, structural stabilization, DxD motif for metal ion binding, and finally ribose binding.
The Bergmann degradation is intended for and has been used as a method for peptide sequencing. It was also proposed for use in cleaving the 3,4-bond of the penicillin nucleus. The compound 2,2-dimethyl-6-phthalimido-3-penamyl isocyanate was arrived at through various means, including the Curtius rearrangement, and it was envisioned that it could undergo the Bergmann degradation to form the desired aldehyde as well as the urea by-product. Though the Bergmann degradation was indeed possible, it was discovered that simple dilute acid hydrolysis would suffice in forming the desired product.
The 1993 film Jurassic Park (based on the 1990 Michael Crichton novel of the same name) features dinosaurs that were genetically altered so that they could not produce the amino acid lysine. This was known as the "lysine contingency" and was supposed to prevent the cloned dinosaurs from surviving outside the park, forcing them to be dependent on lysine supplements provided by the park's veterinary staff. In reality, no animals are capable of producing lysine (it is an essential amino acid). Autotroph Bradytroph "Regulation of endosomal clathrin and retromer-mediated endosome to Golgi retrograde transport by the J-domain protein RME-8" - The EMBO Journal "Pleiotropic effects of purine auxotrophy inRhizobium meliloti on cell surface molecules" - Springerlink "Auxotrophy and Organic Compounds in the Nutrition of Marine Phytoplankton"
Sources: en.wikipedia.org
Galega officinalis (French lilac) was used in diabetes treatment for centuries. In the 1920s, guanidine compounds were discovered in Galega extracts. Animal studies showed that these compounds lowered blood glucose levels. Some less toxic derivatives, synthalin A and synthalin B, were used for diabetes treatment, but after the discovery of insulin, their use declined. Biguanides were reintroduced into Type 2 diabetes treatment in the late 1950s. Initially phenformin was widely used, but its potential for sometimes fatal lactic acidosis resulted in its withdrawal from most pharmacopeias (in the U.S. in 1978). Metformin has a much better safety profile, and it is the principal biguanide drug used in pharmacotherapy worldwide.
GPCRs become desensitized when exposed to their ligand for a long period of time. There are two recognized forms of desensitization: 1) homologous desensitization, in which the activated GPCR is downregulated; and 2) heterologous desensitization, wherein the activated GPCR causes downregulation of a different GPCR. The key reaction of this downregulation is the phosphorylation of the intracellular (or cytoplasmic) receptor domain by protein kinases. Cyclic AMP-dependent protein kinases (protein kinase A) are activated by the signal chain coming from the G protein (that was activated by the receptor) via adenylate cyclase and cyclic AMP (cAMP). In a feedback mechanism, these activated kinases phosphorylate the receptor. The longer the receptor remains active the more kinases are activated and the more receptors are phosphorylated. In β2-adrenoceptors, this phosphorylation results in the switching of the coupling from the Gs class of G-protein to the Gi class. cAMP-dependent PKA mediated phosphorylation can cause heterologous desensitisation in receptors other than those activated.
The origins of alemtuzumab date back to Campath-1 which was derived from the rat antibodies raised against human lymphocyte proteins by Herman Waldmann and colleagues in 1983. The name Campath derives from the pathology department of Cambridge University. Initially, Campath-1 was not ideal for therapy because patients could, in theory, react against the foreign rat protein determinants of the antibody. To circumvent this problem, Greg Winter and his colleagues humanised Campath-1, by extracting the hypervariable loops that had specificity for CD52 and grafting them onto a human antibody framework. This became known as Campath-1H and serves as the basis for alemtuzumab. While alemtuzumab started life as a laboratory tool for understanding the immune system, within a short time it was clinically investigated for use to improve the success of bone marrow transplants and as a treatment for leukaemia, lymphoma, vasculitis, organ transplants, rheumatoid arthritis and multiple sclerosis.
Sources: en.wikipedia.org
It means adding liquid to a lyophilized peptide powder so it dissolves into solution. The dry powder is not a finished liquid product, and the resulting concentration depends on the volume added. Complete dissolution should be visually confirmed before use.
Some peptides have hydrophobic regions or strong charge interactions that make water a poor solvent alone. A small amount of organic solvent, acid, or base may be needed before aqueous dilution. The appropriate approach depends on sequence and should be based on documented compatibility.
No. Solutions can degrade through hydrolysis, oxidation, aggregation, and microbial growth, and stability varies widely by peptide. Storage at reduced temperature and avoidance of repeated freeze-thaw cycles are common laboratory practices. Specific shelf lives are determined by stability testing, not by a general rule.
Storage time depends on peptide sequence, concentration, solvent, and temperature. No single shelf life applies to all peptides. Stability should be determined by analytical testing for the specific preparation.